Home/Pipeline/ISB 830

ISB 830

Oncology (Undisclosed)

PreclinicalActiveN/A

Key Facts

Indication

Oncology (Undisclosed)

Phase

Preclinical

Status

Active

Company

Glenmark Pharmaceuticals

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals has evolved from its 1977 founding into a diversified, global pharmaceutical enterprise with a strategic focus on innovation and accessibility. Under the leadership of Chairman & Managing Director Glenn Saldanha, the company has built significant capabilities in R&D, biologics, and complex generics, supported by a robust pipeline of 25+ candidates and a global commercial footprint. Its strategy centers on advancing a focused pipeline in respiratory, dermatology, and oncology through its biotech arm Ichnos Glenmark Innovation (IGI), while simultaneously scaling its generics and branded formulations business across emerging and developed markets.

View full company profile

Therapeutic Areas

Dermatology Respiratory Oncology

Other Oncology (Undisclosed) Drugs

Drug	Company	Phase	Status
CLD-601	Calidi Biotherapeutics	Discovery	Active
Protease Inhibitor Discovery Programs	Medivir	Discovery	Active
Nucleoside/Nucleotide Discovery Programs	Medivir	Discovery	Active
Orion Collaboration Program 1	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 2	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 3	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 4-6 (Extended)	Glykos Finland	Research	Active
TEM-1	Tempus AI	Discovery/Preclinical	Active
TEM-2	Tempus AI	Discovery/Preclinical	Active
TEM-3	Tempus AI	Discovery/Preclinical	Active
TEM-4	Tempus AI	Discovery/Preclinical	Active
TEM-5	Tempus AI	Discovery/Preclinical	Active